A-dmDT390-anti-CD3 immunotoxin

Drug Profile

A-dmDT390-anti-CD3 immunotoxin

Alternative Names: A-dmDT390-bisFv; A-dmDT390-bisFv(UCHT1); Anti-CD3 antibody-diphtheria toxin conjugate; Anti-CD3 bivalent antibody-diphtheria toxin conjugate; LAX-699; Recombinant anti-CDR-bi-single-chain-Fv-diptheria toxin fusion protein; Resimmune; UCHT-1-Angimmune

Latest Information Update: 20 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Angimmune; University of Louisville
  • Class Immunotoxins; Peptides
  • Mechanism of Action Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cutaneous T cell lymphoma; Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Angimmune plans a phase I/II trial for Melanoma (late-stage disease; Adjunctive therapy) in USA (NCT02990416)
  • 30 Nov 2016 Angimmune completes a phase II trial in Cutaneous T-cell lymphoma in USA (NCT00611208)
  • 22 Nov 2016 Angimmune terminates a phase-I/II clinical trial in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT01888081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top